TUBA1C orchestrates the immunosuppressive tumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma
TUBA1C is a pivotal regulator in ccRCC, affecting both disease progression and the effectiveness of ICB therapy by fostering an immunosuppressive microenvironment mediated by the PI3K/AKT pathway. Additionally, TUBA1C holds promise, both as a prognostic biomarker and a therapeutic target, for enhancing responsiveness to ICB.
Authors
- Qingfei Cao
- Meixue Chen (ORCID: https://orcid.org/0000-0001-9795-1889)
- Junyi Li (ORCID: https://orcid.org/0000-0001-8435-2262)
- Ming Tong (ORCID: https://orcid.org/0000-0002-4532-5269)
Institutions
- Jinzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-09-05
- DOI
- https://doi.org/10.3389/fimmu.2024.1457691
- Citations
- 3
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.55